Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...
Zacks.com on MSN1d
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on UpdatesIt was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...
Hosted on MSN2d
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock UpSage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Zacks.com on MSN19h
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...
Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback